According to Vistagen, the US Patent and Trademark Office (USPTO) has granted US Patent 11,419,881 covering the company’s PH80 pherine nasal spray for treatment of migraine until 2040. The company says that “PH80 is an investigational pherine nasal spray designed with a potential rapid-onset mechanism of action that is fundamentally differentiated from all currently approved treatments for migraine.”
Vistagen recently announced that it was acquiring Pherin Pharmaceuticals, which had been developing PH80. In addition to PH80, Vistagen now fully owns the rights to PH15 for cognitive improvement and PH284, which is in development for the treatment of eating disorders, as well as PH10 and PH94B, which it had previously licensed from Pherin.
Read the Vistagen press release.
